Encoded Therapeutics

Encoded Therapeutics, Inc. is a South San Francisco-based biotechnology company developing precision gene therapies for severe neurological and genetic disorders. Its approach centers on engineering the regulatory elements of gene therapy constructs — promoters, enhancers and 3' untranslated regions — so that a transgene is expressed selectively in the disease-relevant cell types, principally in the brain. The company describes its aim as overcoming limitations of first-generation gene therapy by conferring greater gene specificity, cell selectivity and potency.

The lead program, ETX101, targets SCN1A for SCN1A+ Dravet syndrome, a developmental and epileptic encephalopathy that the company states occurs in roughly 1 in 16,000 births worldwide and is most often caused by loss-of-function variants in SCN1A. ETX101 uses cell-selective targeting of GABAergic neurons together with endogenous gene upregulation via an engineered transcription factor, and per the company's pipeline page has reached pivotal stage. Additional programs include ETX301 for post-amputation neuroma pain (target SCN9A/NaV1.7, nociceptor-selective miRNA knockdown, IND-enabling), a preclinical Angelman syndrome program targeting the UBE3A antisense transcript via unsilencing, and a preclinical Alzheimer's disease/tauopathies program using miRNA knockdown of intracellular tau.

The company is described as a fully integrated organization spanning discovery, manufacturing, clinical development and regulatory affairs, with in-house laboratory operations at its South San Francisco headquarters.

Founding story

Kartik Ramamoorthi, Ph.D. and Stephanie Tagliatela are named as co-founders; Ramamoorthi serves as chief executive officer and Tagliatela as chief scientific officer, both also board members. Both conducted doctoral research in molecular and cellular neuroscience at MIT, and Ramamoorthi previously served on the team that launched Voyager Therapeutics. The company's name derives from the epigenetic code that controls when and where genes are expressed.

Business model

Encoded is a clinical-stage therapeutics developer funded by venture and crossover investors; it advances proprietary gene therapy candidates from discovery through clinical development, with stated capabilities to develop and manufacture one-time gene therapies itself. Sources do not describe product revenue or partnering arrangements.

Not described in the sources; the company is a pre-commercial therapeutics developer financed through equity rounds.

Traction

ETX101 received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for SCN1A+ Dravet syndrome (announced July 2020). The pipeline page lists ETX101 at pivotal stage, ETX301 at IND-enabling, and Angelman syndrome and Alzheimer's/tauopathies programs at preclinical stage. In May 2026 the company reported dosing the first patient in a pivotal ETX101 study and presented POLARIS Phase 1/2 clinical data at the ASGCT 2026 Presidential Symposium.

Latest developments

Company news listings dated May 2026 report: presentation of new POLARIS Phase 1/2 clinical data for ETX101 in Dravet syndrome at the ASGCT 2026 Presidential Symposium (May 13, 2026); presentation of new preclinical data on precision vector engineering across neurology programs at ASGCT 2026 (May 12, 2026); and dosing of the first patient in a pivotal study of ETX101 along with broader portfolio progress (May 06, 2026).